More Company News

ANGLE

Novel assay predicts malignancy in pelvic mass
12 Sep 2022Read More

ANGLE

Novel insights into metastasis in NSCLC
28 Jul 2022Read More

ANGLE

Parsortix enables cancer DNA analysis in NSCLC
20 Jul 2022Read More

ANGLE

Results of capital raise
15 Jul 2022Read More

ANGLE

Proposed placing
14 Jul 2022Read More

ANGLE

Breast cancer spread accelerates during sleep
27 Jun 2022Read More

ANGLE

Repeat Pharma Services business
22 Jun 2022Read More

ANGLE

Predicting immunotherapy response in SCLC
16 Jun 2022Read More

ANGLE

Potential role of invasive cellular protrusions
14 Jun 2022Read More

ANGLE

Partnership with major US urology group
30 May 2022Read More

1 2 3 4 5 6
Return to ANGLE
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).